SCHEMBL1703418

SCHEMBL1703418

O=[N+]([O-])c1nccc(Cl)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TXNRD1 Q16881 3/20 0.39
TDP1 Q9NUW8 4/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
S1PR4 O95977 1/20 0.36
PDE10A Q9Y233 1/20 0.35
MAPT P10636 3/20 0.35
HTT P42858 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 2/20 0.35
PKM P14618 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
HSP90AA1 P07900 1/20 0.35
OPRK1 P41145 1/20 0.35
MERTK Q12866 1/20 0.35
GSR P00390 2/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3293002 0.77 PDE10A (0.36) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL251218 0.75 PDE10A (0.35) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL3826741 0.75 ROCK1 (0.39) ALDH1A1MEN1KMT2APDE10AMAPT
SCHEMBL8665016 0.75 MAPT (0.39) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL2796279 0.73 ALDH1A1 (0.39) TXNRD1TDP1ALDH1A1KMT2AMAPT
SCHEMBL28940336 0.72 PDE10A (0.33) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL17674175 0.71 KDM4E (0.47) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL57064 0.69
SCHEMBL1425910 0.68 PIN1 (0.36) ALDH1A1KDM4EMAPTHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL17225086 0.67 PDE10A (0.42) TDP1ALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120987921-A Preparation method of pazopanib and intermediate thereof 南京亿华药业有限公司 2025-11-21 CN disclosed
US-10844064-B2 sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2020-11-24 US disclosed
US-10414768-B2 Compounds for treating cystic fibrosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2019-09-17 US disclosed
US-9993491-B2 Guanine riboswitch binding compounds and their use as antibiotics SOCPRA—SCIENCES ET GÉNIE S.E.C. (CA) 2018-06-12 US disclosed
US-20180155345-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-06-07 US disclosed
US-20170362239-A1 COMPOUNDS FOR TREATING CYSTIC FIBROSIS UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2017-12-21 US disclosed
EP-3226861-A2 COMPOUNDS FOR TREATING CYSTIC FIBROSIS Centre National de la Recherche Scientifique (CNRS) (FR) 2017-10-11 EP disclosed
EP-3194386-A2 SGC STIMULATORS Ironwood Pharmaceuticals, Inc. (US) 2017-07-26 EP disclosed
WO-2016087665-A2 COMPOUNDS FOR TREATING CYSTIC FIBROSIS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2016-06-09 WO disclosed
WO-2016044446-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2016-03-24 WO disclosed
EP-0283742-A2 Fatty acid amides as inhibitors of acyl-CoA: cholesterol acyltransferase WARNER-LAMBERT COMPANY (US) 1988-09-28 EP disclosed
US-4743605-A PREVENT ABSORPTION OF CHOLESTEROL WARNER-LAMBERT COMPANY (US) 1988-05-10 US disclosed
EP-0138995-A4 REGULATION OF ENZYMES WHICH UTILIZE TETRAHYDROBIOPTERIN OR TETRAHYDROFOLATE COFACTORS WITH 6, 6-DISUBSTITUTED-TETRAHYDROPTERIDINES. UNIV SOUTH ALABAMA (US) 1988-05-10 EP disclosed
US-4716175-A INHIBITION OF INTESTINAL ABSORPTION OF CHOLESTEROL WARNER-LAMBERT COMPANY (US) 1987-12-29 US disclosed
EP-0138995-A1 REGULATION OF ENZYMES WHICH UTILIZE TETRAHYDROBIOPTERIN OR TETRAHYDROFOLATE COFACTORS WITH 6, 6-DISUBSTITUTED-TETRAHYDROPTERIDINES. UNIV SOUTH ALABAMA (US) 1985-05-02 EP disclosed
EP-0039037-B1 PYRIMIDYLTHIO-UREAS, MEDICINES CONTAINING THEM AND THEIR USE Beiersdorf Aktiengesellschaft (DE) 1985-01-16 EP disclosed
WO-1984004040-A1 REGULATION OF ENZYMES WHICH UTILIZE TETRAHYDROBIOPTERIN OR TETRAHYDROFOLATE COFACTORS WITH 6, 6-DISUBSTITUTED-TETRAHYDROPTERIDINES UNIV SOUTH ALABAMA (US) 1984-10-25 WO disclosed
US-4434167-A Pyrimidyl thioureas useful for the treatment of hypertension and hyperlipidemia BEIERSDORF AKTIENGESELLSCHAFT (DE) 1984-02-28 US disclosed
EP-0039037-A1 Pyrimidylthio-ureas, medicines containing them and their use Beiersdorf Aktiengesellschaft (DE) 1981-11-04 EP disclosed
US-4014677-A HERBICIDES CIBA-GEIGY CORPORATION (US) 1977-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10414768-B2 Compounds for treating cystic fibrosis CFTR, ABCB11, SLC26A4 TXNRD1 2098/4885TDP1 4086/4885ALDH1A1 186/4885
US-20170362239-A1 COMPOUNDS FOR TREATING CYSTIC FIBROSIS CFTR, ABCB11, SLC26A4 TXNRD1 2098/4885TDP1 4086/4885ALDH1A1 186/4885
US-10844064-B2 sGC stimulators GUCY1B1, GUCY1A1, PRKG1 TXNRD1 385/4885TDP1 1148/4885ALDH1A1 1902/4885
US-20180155345-A1 sGC STIMULATORS GUCY1B1, GUCY1A1, PRKG1 TXNRD1 385/4885TDP1 1148/4885ALDH1A1 1902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.